Cell Function
Merck KGaA Discontinues Xevinapant Program in Locally Advanced Head and Neck Cancer Due to Phase III Trial Failure
Merck KGaA, xevinapant, Phase III trial, head and neck cancer, TrilynX study, X-Ray Vision study, oncology pipeline, apoptosis proteins inhibitor
Ikena Oncology Cuts Hippo Pathway Inhibitor, Lays Off Half of Staff in Strategic Reprioritization
Ikena Oncology, Hippo pathway inhibitor, TEAD1-selective, layoffs, strategic update, biotech industry, clinical trials, cancer treatment
BIO Undergoes Transformative Restructuring for Future Growth
BIO, lobbying group, reorganization, restructuring, layoffs, future growth, transformation, biotechnology industry.
Lilly Expands Radiopharmaceutical Portfolio with Aktis Acquisition
Lilly, Aktis, radiopharmaceutical, acquisition, portfolio, cancer therapy, targeted treatment
Progentos Secures $65 Million for Groundbreaking Remyelination Therapy in Multiple Sclerosis Treatment
Progentos, funding, remyelination therapy, multiple sclerosis, MS treatment, clinical trials, neurodegenerative diseases, nervous system repair, biotechnology.
BridgeBio Launches KRAS-Targeted Cancer Startup with $200 Million in Venture Capital Funding
BridgeBio, KRAS, cancer, startup, venture capital, funding, newco, oncology, precision medicine, targeted therapies.
Novartis Invests $180M in PeptiDream to Boost Radiopharmaceutical Development
Novartis, PeptiDream, radiopharmaceuticals, investment, drug development, partnership, targeted therapies, cancer treatment, radioactive isotopes.
FDA Fast-Tracks Day One’s Innovative Therapy for Pediatric Brain Tumors
FDA, accelerated approval, Day One, targeted treatment, pediatric brain tumors, glioma, children, cancer treatment, innovative therapy.
Revolutionizing Research and Development: Xaira Unveils AI-Driven Platform with $1B Funding and Former Genentech Leaders
AI-Powered Xaira, $1B funding, Genentech executives, R&D transformation, biotechnology innovation, artificial intelligence in research, life sciences advancement.
Arrowhead’s Plozasiran Projected to Surpass $700M in Sales by 2032, Addressing Major Unmet Needs in Dyslipidemia Treatment
Arrowhead Pharmaceuticals, Plozasiran, Dyslipidemia, GlobalData, Sales Forecast, $700M, 2032, Unmet Needs, Triglyceride Reduction, APOC3 Targeting, SHTG (Severe Hypertriglyceridemia), FCS (Familial Chylomicronemia Syndrome), Mixed Dyslipidemia